Overland Pharmaceuticals is focused on advancing innovative therapies, particularly in the field of oncology, through a cross-border platform that emphasizes strategic partnerships and in-house research and development (R&D). The company is building a portfolio that includes first-in-class antibody-drug conjugates (ADCs) and allogeneic cell therapies, specifically targeting the Greater China and Asian markets. By leveraging collaborations with established biotech firms, Overland aims to address significant clinical unmet needs and drive the development and commercialization of cutting-edge medical advancements.

One of the key technologies highlighted by Overland Pharmaceuticals is the use of ADCs, such as ZYNLONTA® (loncastuximab tesirine), which is designed to target CD19-expressing cells. This innovative approach involves the internalization of the ADC into the cancer cell, where it releases a potent payload that binds to DNA, leading to cell cycle arrest and subsequent tumor cell death. Overland is actively conducting clinical trials to evaluate the efficacy and safety of ZYNLONTA in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in Chinese patients, showcasing their commitment to bringing effective treatment options to underserved populations.

China

Founded in 2020, Overland Pharmaceuticals is establishing a leading cross-border platform company focused on advanced modalities through strategic partnering and in-house R&D. Overland is seeded by Hillhouse Capital with access to global innovation and China biopharma ecosystem.

Overland is building an initial oncology portfolio of first-in-class ADC and allogeneic cell therapy programs for greater China and Asia through partnering with established biotechs.

Through formative R&D partnerships and in-house technology platforms, Overland will move forward the development and commercialization of the most promising advances in medicine.

Overland Pharmaceuticals

Company Details